NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$445.00
Cat.#: 28239 |
Product Name: Anti-CD142(DMC463) IgG1 Chimeric Monoclonal Antibody |
Synonyms: TF; Coagulation factor III; F3 |
Description: Anti-CD142 antibody(DMC463) IgG1 Chimeric Monoclonal Antibody |
Background: This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades; and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades; which circulate as nonfunctional precursors; this factor is a potent initiator that is fully functional when expressed on cell surfaces; for example; on monocytes. There are 3 distinct domains of this factor: extracellular; transmembrane; and cytoplasmic. Platelets and monocytes have been shown to express this coagulation factor under procoagulatory and proinflammatory stimuli; and a major role in HIV-associated coagulopathy has been described. Platelet-dependent monocyte expression of coagulation factor III has been described to be associated with Coronavirus Disease 2019 (COVID-19) severity and mortality. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq; Aug 2020] |
Applications: Flow Cyt |
Recommended Dilutions: Flow Cyt 1:100 |
Host Species: Rabbit |
Isotype: Rabbit:Human Fc chimeric IgG1 |
Purification: Purified from cell culture supernatant by affinity chromatography |
Species Reactivity: Human CD142 |
Constituents: Lyophilized from sterile PBS, pH 7.4. 5 % – 8% trehalose is added as protectants before lyophilization. |
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). |
Figure 1. Flow cytometry analysis with Anti-CD142 (DMC463) on Expi293 cells transfected with human CD142 (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram). |